An Oxidative Stress-Related Genes Signature for Predicting Survival in Bladder Cancer: Based on TCGA Database and Bioinformatics
Min Zhang,Gang Du,Zhengtian Li,Dehui Li,Weichao Li,Hening Li,Xingxin Gao,Zhanhong Tang
DOI: https://doi.org/10.2147/IJGM.S348945
IF: 2.145
2022-03-08
International Journal of General Medicine
Abstract:Min Zhang, 1, &ast Gang Du, 2, &ast Zhengtian Li, 2 Dehui Li, 3 Weichao Li, 2 Hening Li, 4 Xingxin Gao, 3 Zhanhong Tang 1 1 Department of Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, People's Republic of China; 2 Department of Bone and Joint Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, People's Republic of China; 3 Department of Burns and Plastic, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, People's Republic of China; 4 Guangxi Medical University, Nanning, 530021, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhanhong Tang; Xingxin Gao, Email ; Background: Oxidative stress (OS) responses have been linked to oncogenesis and tumor progression and have recently been regarded as a potential strategy for tumor therapy. However, OS-related therapeutic targets have not been identified to date in the bladder cancer (BC). Methods: The mRNA expression and clinical data of BC were downloaded from the public database. Prognostic risk score signature was constructed using LASSO Cox regression analysis. External validation was performed in GSE15307 cohort. ESTIMATE, CIBERSORT, and ssGSEA algorithm were used to analyze immune cell infiltration and immune microenvironment. Next, functional enrichment analysis was performed to elucidate the mechanism underlying the signature. Additionally, we performed a nomogram to forecast the survival rate of individual BC patients. Results: An OS-related genes (OSRGs) signature was constructed. Overall survival was lower in the high-risk group than in the low-risk group, according to survival analyses. The area under the curve (AUC) of ROC curves further validated the prognostic signature's strong prediction performance in these two cohorts. The risk score was verified as an independent risk factor for BC by independent prognostic analysis. Moreover, as compared to TNM stage alone, a nomogram that integrated the risk score with TNM stage showed a much superior predictive value. Immune infiltration and tumor microenvironment studies indicated that immune cells and functions may play a significant role in carcinogenesis and development. The levels of expression of prognostic genes were shown to be substantially linked with drug sensitivity. Conclusion: We developed a novel OSRGs signature for predicting overall survival and impacting the immune status in patients with BC. New nomogram can help clinicians predict the survival rate of BC patients. These findings shed new light on the potential usage of OSRGs signature in BC patients. Keywords: bladder cancer, oxidative stress, prognosis, risk signature, immune cell infiltration, drug sensitivity Bladder cancer is the tenth most prevalent kind of cancer globally, with a morbidity rate of 3.0% and a death rate of 2.1%. 1 Approximately 75% of bladder cancer cases are classified as non-muscle invasive bladder cancer (NMIBC), and 25% are classified as muscle invasive bladder cancer (MIBC). 2 Although NMIBC can be treated by surgery, it often relapses further after resection, and approximately 15% of cases deteriorate to MIBC, which is related to more aggressive characteristics and poor prognosis. 3 The traditional pathological grade and clinical TNM stage are currently utilized to evaluate the prognosis of BC patients. BC with early metastasis is associated with poor prognosis and poor therapeutic outcomes owing to the lack of reliable screening techniques for early diagnosis. Some studies have reported that the mutation of tumor suppressor genes to oncogenes, such as HER-2, H-Ras and Bcl-2, promotes the occurrence of BC. 4 In recent years, the advent of novel molecularly targeted medicines opens up new avenues for the treatment of advanced BC. Targeted molecular therapy has progressively emerged as a viable option in cancer treatment. Many research has concentrated on developing more effective prediction signatures that might better elucidate the variables that contribute to the prognosis and progression and even more specific immune landscape as well efficacy of immunotherapy of BC, with the goal of providing more evidence for individual molecular therapy methods. Although BC has been extensively studied, few validated biomarkers or screening tools general exist in clinical. Hence, there exists an urgency to develop a robust biomarker to predict prognosis and guide therapeutic treatment, particularly in the areas of targeted therapy and immunotherapy for BC patients. Oxidative stres -Abstract Truncated-
medicine, general & internal